Cryoport Inc (CYRX) 1.96 $CYRX Cryoport and Dat
Post# of 273254
Posted On: 09/25/2016 9:18:28 PM
Cryoport Inc (CYRX) 1.96 $CYRX
Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process
PR Newswire - Thu Sep 22, 3:15PM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company dedicated to the life sciences, today announced the integration of its proprietary logistics technology, the Cryoportal(TM), with Database Integrations, Inc.'s Integrated Cell Therapy Automated Network (iCAN) scheduling platform. The integration of these two platforms is designed to solve the challenges of manufacturing, distribution and global supply chain planning for the clinical development and commercialization of cell and gene therapy products.
CYRX: 1.96 (-0.11), IMUC: 0.12 (unch)
Cryoport Provides Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline
PR Newswire - Mon Sep 12, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present at the 2nd Annual CAR &TCR Summit 2016 in Boston, as follows:
CYRX: 1.96 (-0.11)
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
PR Newswire - Mon Aug 29, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" , the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services ("KCAS" and Heat Biologics, Inc. ("Heat" .
HTBX: 1.44 (+0.07), CYRX: 1.96 (-0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Cryoport, Inc. - CYRX
ACCESSWIRE - Mon Aug 15, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / August 15, 2016 / Levi & Korsinsky announces it has commenced an investigation of Cryoport, Inc. (NASDAQ: CYRX) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/cryoport-cyrx or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
CYRX: 1.96 (-0.11)
Cryoport Expands Agreement with Stemedica to Support a Phase II Clinical Trial to Assess a Stem Cell Therapy for the Treatment of Alzheimer's Disease
PR Newswire - Thu Aug 11, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" , the world's leading cryogenic logistics company, today announced it has expanded its contract with Stemedica Cell Technologies, Inc. ("Stemedica" to provide cold chain logistics support for a Phase II clinical trial to assess the safety, tolerability and preliminary efficacy of allogeneic stem cell-based therapies in the treatment of Alzheimer's disease.
CYRX: 1.96 (-0.11)
Cryoport to Support World-Leading Life Science Company's Custom Development and Biologics Manufacturing Business
PR Newswire - Tue Aug 02, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" , the world's leading cryogenic logistics company, today announced that one of the world's foremost contract manufacturers to the biopharma industry ("the Client" will convert its fleet of liquid nitrogen dewars supporting shipping of its contract manufacturing biologics and cell therapy businesses to Cryoport's industry-leading and comprehensive logistics solutions. Cryoport solutions include comprehensive order entry information, customs management, innovative real time tracking, intervention where necessary, advanced information technology, and archiving scientific and regulatory information.
CYRX: 1.96 (-0.11)
Cryoport to Report First Quarter Fiscal 2017 Financial Results on August 15th
PR Newswire - Mon Aug 01, 10:35AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company, today announced that the Company will release financial results for the first quarter fiscal year 2017 ended June 30, 2016 on August 15, 2016 after U.S. markets close. Cryoport will provide an update on revenue from its three main lines of business - Biopharma, Animal Health and Reproductive Medicine. Management will also report on new client activities and provide a general business outlook.
CYRX: 1.96 (-0.11)
Cryoport Successfully Completes Its Rights Offering
PR Newswire - Tue Jun 21, 8:23AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company" , the world's leading cryogenic logistics company, announced that it has received gross proceeds of $1,304,748 in subscriptions for 841,773 shares of common stock from its previously announced rights offering, which expired on Monday, June 20, 2016 at 5:00 p.m. ET.
CYRX: 1.96 (-0.11)
Cryoport Launches Next Generation Condition Monitoring Technology
PR Newswire - Mon Jun 20, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company, announced today the launch of its new SmartPak II(TM) Condition Monitoring System. It is configured to provide end-to-end visibility on the real-time condition and location of critical biological commodities. The SmartPak IITM measures a variety of environmental variables and works in conjunction with the Company's Cryoportal(TM) logistics management platform to provide comprehensive and seamless monitoring of commodity conditions and Cryoport Express(TM) shipper performance. The cloud based Cryoportal(TM) retains all of the critical data analytics generated by the SmartPak IITM, including "chain-of-condition" and "chain-of-custody". Its seamless integration with the Cryoportal(TM) provides, for the first time, real-time intervention capabilities. Automated email alerts are sent to stakeholders for any incident of excursion or deviation.
CYRX: 1.96 (-0.11)
Cryoport Enters Bio-Storage Market
PR Newswire - Wed Jun 15, 8:15AM CDT
Cryoport, Inc. (CYRX) ("Company" , the world's leading cryogenic logistics company, today announced the launch of its bio-storage offering. The new offering is the result of a clear demand from Cryoport customers to complement its leading cryogenic logistics solutions with advanced storage and fulfillment capabilities. Cryoport Biostorage will support cryogenic storage, fulfillment, and transportation of all valuable and often irreplaceable temperature-sensitive biologic material, including clinical trial samples, vaccines, stem cells, regenerative therapies, bio-markers and immunotherapies.
CYRX: 1.96 (-0.11)
Cryoport Reminds Record Date Rights Holders for the Rights Offering to Submit all Subscriptions to Their Broker or Subscription Agent
PR Newswire - Fri Jun 10, 8:21AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company" , the world's leading cryogenic logistics company, would like to remind its rights offering shareholders and warrant holders of record that they have the right, but not the obligation, to exercise their non-transferable basic subscription rights for $1.55 per common share, which allows its shareholders and warrant holders of record to acquire additional shares of common stock (the "rights offering" .
CYRX: 1.96 (-0.11)
Cryoport Signs Strategic Agreement to Support Tissue Solutions Transportation of Human Cells and Cryopreserved Cell Lines
PR Newswire - Wed Jun 08, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" announced today that its industry leading cryogenic logistics solutions, including cryogenic shipping, logistics support and chain of condition monitoring, are supporting Tissue Solutions ("Tissue Solutions" as it transports products from their global network of more than 100 locations. Tissue Solutions is a leading supplier of human bio specimens to the pharmaceutical and biotech industries worldwide, specializing in the supply of high quality, ethically sourced human tissue and bio fluids for clinical trial programs.
CYRX: 1.96 (-0.11)
Worthington Industries Scales New 52-Week High of $39.75
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 1:47PM CDT
Shares of Worthington Industries Inc. (WOR) touched a new 52-week high of $39.75 yesterday before retracing to end the day at $39.61.
CYRX: 1.96 (-0.11), KALU: 85.42 (-0.50), WOR: 44.17 (+0.55), X: 18.95 (+0.75)
Cryoport Reminds All Interested Parties That Today is the Final Day to Become a Rights Offering Record Date Holder
PR Newswire - Wed May 25, 8:15AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company" , the world's leading cryogenic logistics company,would like to remind the investment community that an investor must own CYRX, CYRXW or any other Cryoport warrants by 4:00 PM ET on Wednesday, May 25, 2016 in order to be considered a record date holder for purposes of the Rights Offering.
CYRX: 1.96 (-0.11)
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
PR Newswire - Mon May 23, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO" for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
CYRX: 1.96 (-0.11)
Cryoport Announces Share Pricing Period and Record Date for Shareholder and Warrant Holder Rights Offering
PR Newswire - Mon May 16, 7:49AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" , the world's leading cryogenic logistics company, announced today the pricing period and record date for its rights offering.
CYRX: 1.96 (-0.11)
Cryoport Agreement with Cryo Store BV Expands European Presence for its Best-in-Class Cryogenic Logistics Solutions
PR Newswire - Fri May 06, 8:15AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company, today announced that Cryo Store BV ("Cryo Store" , a European biostorage company, will utilize Cryoport's cryogenic logistics solutions to better serve the logistics needs of life sciences customers. Cryo Store provides storage and distribution services for temperature-controlled goods to biotechnology and pharmaceutical companies in Europe.
CYRX: 1.96 (-0.11)
Cryoport Files S-1 Registration Statement for Rights Offering
PR Newswire - Fri Apr 29, 12:43PM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company" , the world's leading cryogenic logistics company, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its shareholders and warrant holders of record.
CYRX: 1.96 (-0.11)
Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process
PR Newswire - Thu Sep 22, 3:15PM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company dedicated to the life sciences, today announced the integration of its proprietary logistics technology, the Cryoportal(TM), with Database Integrations, Inc.'s Integrated Cell Therapy Automated Network (iCAN) scheduling platform. The integration of these two platforms is designed to solve the challenges of manufacturing, distribution and global supply chain planning for the clinical development and commercialization of cell and gene therapy products. CYRX: 1.96 (-0.11), IMUC: 0.12 (unch)
Cryoport Provides Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline
PR Newswire - Mon Sep 12, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present at the 2nd Annual CAR &TCR Summit 2016 in Boston, as follows: CYRX: 1.96 (-0.11)
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
PR Newswire - Mon Aug 29, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services ("KCAS" and Heat Biologics, Inc. ("Heat" . HTBX: 1.44 (+0.07), CYRX: 1.96 (-0.11)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Cryoport, Inc. - CYRX
ACCESSWIRE - Mon Aug 15, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / August 15, 2016 / Levi & Korsinsky announces it has commenced an investigation of Cryoport, Inc. (NASDAQ: CYRX) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/cryoport-cyrx or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
CYRX: 1.96 (-0.11)
Cryoport Expands Agreement with Stemedica to Support a Phase II Clinical Trial to Assess a Stem Cell Therapy for the Treatment of Alzheimer's Disease
PR Newswire - Thu Aug 11, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company, today announced it has expanded its contract with Stemedica Cell Technologies, Inc. ("Stemedica" to provide cold chain logistics support for a Phase II clinical trial to assess the safety, tolerability and preliminary efficacy of allogeneic stem cell-based therapies in the treatment of Alzheimer's disease. CYRX: 1.96 (-0.11)
Cryoport to Support World-Leading Life Science Company's Custom Development and Biologics Manufacturing Business
PR Newswire - Tue Aug 02, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company, today announced that one of the world's foremost contract manufacturers to the biopharma industry ("the Client" will convert its fleet of liquid nitrogen dewars supporting shipping of its contract manufacturing biologics and cell therapy businesses to Cryoport's industry-leading and comprehensive logistics solutions. Cryoport solutions include comprehensive order entry information, customs management, innovative real time tracking, intervention where necessary, advanced information technology, and archiving scientific and regulatory information. CYRX: 1.96 (-0.11)
Cryoport to Report First Quarter Fiscal 2017 Financial Results on August 15th
PR Newswire - Mon Aug 01, 10:35AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company, today announced that the Company will release financial results for the first quarter fiscal year 2017 ended June 30, 2016 on August 15, 2016 after U.S. markets close. Cryoport will provide an update on revenue from its three main lines of business - Biopharma, Animal Health and Reproductive Medicine. Management will also report on new client activities and provide a general business outlook. CYRX: 1.96 (-0.11)
Cryoport Successfully Completes Its Rights Offering
PR Newswire - Tue Jun 21, 8:23AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"
, the world's leading cryogenic logistics company, announced that it has received gross proceeds of $1,304,748 in subscriptions for 841,773 shares of common stock from its previously announced rights offering, which expired on Monday, June 20, 2016 at 5:00 p.m. ET. CYRX: 1.96 (-0.11)
Cryoport Launches Next Generation Condition Monitoring Technology
PR Newswire - Mon Jun 20, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company, announced today the launch of its new SmartPak II(TM) Condition Monitoring System. It is configured to provide end-to-end visibility on the real-time condition and location of critical biological commodities. The SmartPak IITM measures a variety of environmental variables and works in conjunction with the Company's Cryoportal(TM) logistics management platform to provide comprehensive and seamless monitoring of commodity conditions and Cryoport Express(TM) shipper performance. The cloud based Cryoportal(TM) retains all of the critical data analytics generated by the SmartPak IITM, including "chain-of-condition" and "chain-of-custody". Its seamless integration with the Cryoportal(TM) provides, for the first time, real-time intervention capabilities. Automated email alerts are sent to stakeholders for any incident of excursion or deviation. CYRX: 1.96 (-0.11)
Cryoport Enters Bio-Storage Market
PR Newswire - Wed Jun 15, 8:15AM CDT
Cryoport, Inc. (CYRX) ("Company"
, the world's leading cryogenic logistics company, today announced the launch of its bio-storage offering. The new offering is the result of a clear demand from Cryoport customers to complement its leading cryogenic logistics solutions with advanced storage and fulfillment capabilities. Cryoport Biostorage will support cryogenic storage, fulfillment, and transportation of all valuable and often irreplaceable temperature-sensitive biologic material, including clinical trial samples, vaccines, stem cells, regenerative therapies, bio-markers and immunotherapies. CYRX: 1.96 (-0.11)
Cryoport Reminds Record Date Rights Holders for the Rights Offering to Submit all Subscriptions to Their Broker or Subscription Agent
PR Newswire - Fri Jun 10, 8:21AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"
, the world's leading cryogenic logistics company, would like to remind its rights offering shareholders and warrant holders of record that they have the right, but not the obligation, to exercise their non-transferable basic subscription rights for $1.55 per common share, which allows its shareholders and warrant holders of record to acquire additional shares of common stock (the "rights offering" . CYRX: 1.96 (-0.11)
Cryoport Signs Strategic Agreement to Support Tissue Solutions Transportation of Human Cells and Cryopreserved Cell Lines
PR Newswire - Wed Jun 08, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
announced today that its industry leading cryogenic logistics solutions, including cryogenic shipping, logistics support and chain of condition monitoring, are supporting Tissue Solutions ("Tissue Solutions" as it transports products from their global network of more than 100 locations. Tissue Solutions is a leading supplier of human bio specimens to the pharmaceutical and biotech industries worldwide, specializing in the supply of high quality, ethically sourced human tissue and bio fluids for clinical trial programs. CYRX: 1.96 (-0.11)
Worthington Industries Scales New 52-Week High of $39.75
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 1:47PM CDT
Shares of Worthington Industries Inc. (WOR) touched a new 52-week high of $39.75 yesterday before retracing to end the day at $39.61.
CYRX: 1.96 (-0.11), KALU: 85.42 (-0.50), WOR: 44.17 (+0.55), X: 18.95 (+0.75)
Cryoport Reminds All Interested Parties That Today is the Final Day to Become a Rights Offering Record Date Holder
PR Newswire - Wed May 25, 8:15AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (the "Company"
, the world's leading cryogenic logistics company,would like to remind the investment community that an investor must own CYRX, CYRXW or any other Cryoport warrants by 4:00 PM ET on Wednesday, May 25, 2016 in order to be considered a record date holder for purposes of the Rights Offering. CYRX: 1.96 (-0.11)
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
PR Newswire - Mon May 23, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO" for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month. CYRX: 1.96 (-0.11)
Cryoport Announces Share Pricing Period and Record Date for Shareholder and Warrant Holder Rights Offering
PR Newswire - Mon May 16, 7:49AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company, announced today the pricing period and record date for its rights offering. CYRX: 1.96 (-0.11)
Cryoport Agreement with Cryo Store BV Expands European Presence for its Best-in-Class Cryogenic Logistics Solutions
PR Newswire - Fri May 06, 8:15AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company, today announced that Cryo Store BV ("Cryo Store" , a European biostorage company, will utilize Cryoport's cryogenic logistics solutions to better serve the logistics needs of life sciences customers. Cryo Store provides storage and distribution services for temperature-controlled goods to biotechnology and pharmaceutical companies in Europe. CYRX: 1.96 (-0.11)
Cryoport Files S-1 Registration Statement for Rights Offering
PR Newswire - Fri Apr 29, 12:43PM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading cryogenic logistics company, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its shareholders and warrant holders of record. CYRX: 1.96 (-0.11)
(0)
(0)Scroll down for more posts ▼